We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Court Denies Genentech’s Attempt to Block Amgen’s Herceptin Biosimilar
Court Denies Genentech’s Attempt to Block Amgen’s Herceptin Biosimilar
In a blow to Genentech’s blockbuster cancer drug Herceptin, a federal appeals court refused to temporarily suspend sales of Amgen’s biosimilar while a lower court considers a patent infringement challenge.